Alireza Atri

8.8k total citations · 9 hit papers
119 papers, 5.0k citations indexed

About

Alireza Atri is a scholar working on Psychiatry and Mental health, Physiology and Cognitive Neuroscience. According to data from OpenAlex, Alireza Atri has authored 119 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Psychiatry and Mental health, 35 papers in Physiology and 22 papers in Cognitive Neuroscience. Recurrent topics in Alireza Atri's work include Dementia and Cognitive Impairment Research (55 papers), Alzheimer's disease research and treatments (34 papers) and Health Systems, Economic Evaluations, Quality of Life (15 papers). Alireza Atri is often cited by papers focused on Dementia and Cognitive Impairment Research (55 papers), Alzheimer's disease research and treatments (34 papers) and Health Systems, Economic Evaluations, Quality of Life (15 papers). Alireza Atri collaborates with scholars based in United States, Denmark and United Kingdom. Alireza Atri's co-authors include Lynn Shaughnessy, Stephen Salloway, Liana G. Apostolova, Jeffrey L. Cummings, Reisa A. Sperling, Paul Aisen, Joseph J. Locascio, Bradford C. Dickerson, Steven D. Shirk and Dennis J. Selkoe and has published in prestigious journals such as JAMA, Nature Communications and Journal of Neuroscience.

In The Last Decade

Alireza Atri

112 papers receiving 4.9k citations

Hit Papers

Alterations in Memory Networks in Mild Cognitive Impairme... 2006 2026 2012 2019 2006 2017 2019 2021 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Alterations in Memory Networks in Mild Cognitive Impairment and Alzheimer's Disease: An Independent Component Analysis
    2006 577 citations Bradford C. Dickerson, Alireza Atri et al. Journal of Neuroscience profile →
  2. Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS)
    2017 402 citations Steven D. Shirk, Alireza Atri et al. Alzheimer Disease & Associated Disorders profile →
  3. The Alzheimer’s Disease Clinical Spectrum
    2019 401 citations Alireza Atri profile →
  4. Aducanumab: Appropriate Use Recommendations
    2021 207 citations Paul Aisen, Alireza Atri et al. profile →
  5. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
    2023 159 citations Harald Hampel, Min Cho et al. profile →
  6. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
    2021 155 citations Jeffrey L. Cummings, Paul Aisen et al. Alzheimer s Research & Therapy profile →
  7. Aducanumab: Appropriate Use Recommendations Update
    2022 126 citations Jeffrey L. Cummings, Alireza Atri et al. profile →
  8. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
    2025 40 citations Jeffrey L. Cummings, Alireza Atri et al. Alzheimer s Research & Therapy profile →
  9. Donanemab: Appropriate use recommendations
    2025 39 citations Suzanne E. Schindler, Alireza Atri et al. profile →

Peers

Alireza Atri
J. Wesson Ashford United States
Andrew Satlin United States
Eric McDade United States
David Geldmacher United States
Craig Ritchie United Kingdom
Jakub Hort Czechia
Anne Corbett United Kingdom
Shobha Dhadda United States
Chengjie Xiong United States
Anton P. Porsteinsson United States
J. Wesson Ashford United States
Alireza Atri
Citations per year, relative to Alireza Atri Alireza Atri (= 1×) peers J. Wesson Ashford

Countries citing papers authored by Alireza Atri

Since Specialization
Citations

This map shows the geographic impact of Alireza Atri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alireza Atri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alireza Atri more than expected).

Fields of papers citing papers by Alireza Atri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alireza Atri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alireza Atri. The network helps show where Alireza Atri may publish in the future.

Co-authorship network of co-authors of Alireza Atri

This figure shows the co-authorship network connecting the top 25 collaborators of Alireza Atri. A scholar is included among the top collaborators of Alireza Atri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alireza Atri. Alireza Atri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cummings, Jeffrey L., Alireza Atri, Howard Feldman, et al.. (2025). evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimer s Research & Therapy. 17(1). 14–14. 40 indexed citations breakdown →
2.
Llibre‐Guerra, Jorge J., Eric McDade, Suzanne E. Schindler, et al.. (2025). Towards pharmacological prevention of Alzheimer disease. Nature Reviews Neurology. 21(12). 721–733.
3.
4.
Hampel, Harald, et al.. (2024). Amyloid-related imaging abnormalities (ARIA) and their radiological, biological and clinical characteristics: a plain language summary. Neurodegenerative Disease Management. 14(3-4). 51–62. 3 indexed citations
5.
Adler, Charles H., Nan Zhang, Holly A. Shill, et al.. (2024). Conjugal Synucleinopathies: A Clinicopathologic Study. Movement Disorders. 39(7). 1212–1217. 1 indexed citations
6.
Mastenbroek, Sophie E, Jacob W. Vogel, Lyduine E. Collij, et al.. (2024). Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology. Nature Communications. 15(1). 5133–5133. 30 indexed citations
7.
8.
9.
10.
Dranitsaris, George, et al.. (2023). Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists. Alzheimer s Research & Therapy. 15(1). 60–60. 5 indexed citations
11.
Malek‐Ahmadi, Michael, et al.. (2021). Norms and equivalences for MoCA-30, MoCA-22, and MMSE in the oldest-old. Aging Clinical and Experimental Research. 33(12). 3303–3311. 26 indexed citations
12.
Cummings, Jeffrey L., Paul Aisen, Cynthia A. Lemere, et al.. (2021). Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. 21(2). 111–114. 7 indexed citations
13.
Dickerson, Bradford C., Scott M. McGinnis, Chenjie Xia, et al.. (2017). Approach to atypical Alzheimer’s disease and case studies of the major subtypes. CNS Spectrums. 22(6). 439–449. 55 indexed citations
14.
Mitchell, Meghan, Steven D. Shirk, Donald G. McLaren, et al.. (2015). Recognition of faces and names: multimodal physiological correlates of memory and executive function. Brain Imaging and Behavior. 10(2). 408–423. 9 indexed citations
15.
Atri, Alireza, Susan Rountree, Oscar L. López, & Rachelle S. Doody. (2012). Validity, Significance, Strengths, Limitations, and Evidentiary Value of Real-World Clinical Data for Combination Therapy in Alzheimer’s Disease: Comparison of Efficacy and Effectiveness Studies. Neurodegenerative Diseases. 10(1-4). 170–174. 20 indexed citations
16.
Rosenbloom, Michael & Alireza Atri. (2011). The Evaluation of Rapidly Progressive Dementia. The Neurologist. 17(2). 67–74. 49 indexed citations
17.
Serrano‐Pozo, Alberto, Gloria Lena Vega, Dieter Lütjohann, et al.. (2010). Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers. Alzheimer Disease & Associated Disorders. 24(3). 220–226. 60 indexed citations
18.
19.
Schön, Karin, et al.. (2005). Scopolamine Reduces Persistent Activity Related to Long-Term Encoding in the Parahippocampal Gyrus during Delayed Matching in Humans. Journal of Neuroscience. 25(40). 9112–9123. 113 indexed citations
20.
Atri, Alireza & Volney Sheen. (2003). Cavernous Sinus Syndrome and Headache Due to Bilateral Carotid Artery Aneurysms. Archives of Neurology. 60(9). 1327–8. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Wesson Ashford Breakdown of academic impact, for papers by Andrew Satlin Breakdown of academic impact, for papers by Eric McDade Breakdown of academic impact, for papers by David Geldmacher Breakdown of academic impact, for papers by Craig Ritchie Breakdown of academic impact, for papers by Jakub Hort Breakdown of academic impact, for papers by Anne Corbett Breakdown of academic impact, for papers by Shobha Dhadda Breakdown of academic impact, for papers by Chengjie Xiong Breakdown of academic impact, for papers by Anton P. Porsteinsson
Rankless by CCL
2026